Loomis Sayles & Co. L P Sells 273,522 Shares of Novo Nordisk A/S (NYSE:NVO)

Loomis Sayles & Co. L P cut its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 3.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,623,915 shares of the company's stock after selling 273,522 shares during the period. Novo Nordisk A/S comprises about 1.3% of Loomis Sayles & Co. L P's portfolio, making the stock its 18th largest position. Loomis Sayles & Co. L P owned approximately 0.19% of Novo Nordisk A/S worth $1,026,849,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. International Assets Investment Management LLC increased its stake in Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock worth $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock valued at $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S during the third quarter worth about $98,765,000. Marshall Wace LLP grew its holdings in shares of Novo Nordisk A/S by 34,472.1% during the second quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock worth $98,696,000 after buying an additional 689,441 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $41,646,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. BMO Capital Markets reduced their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NVO traded down $0.50 during midday trading on Monday, reaching $104.56. The stock had a trading volume of 4,291,469 shares, compared to its average volume of 4,509,487. The firm has a market cap of $469.22 billion, a PE ratio of 34.00, a P/E/G ratio of 1.35 and a beta of 0.42. The firm has a 50 day simple moving average of $115.48 and a 200-day simple moving average of $128.81. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.